Watson Pharmaceuticals has increased its generic R&D spending by 17 percent to $37 million during the third quarter as it awaits FDA action on about 60 ANDAs under review. Overall R&D spending grew 15 percent to $52 million, CEO Paul Bisaro said on the drugmaker’s third-quarter earnings call.
Generic Line